R&D News | pharmaphorum

News

Cytokinetics has revealed highly anticipated data from the ACACIA-HCM study of Myqorzo in non-obstructive hypertrophic cardiomyopathy at ESC 2026.

News

Lilly has continued its lengthy streak of acquisitions in 2026 with a $2.88 billion agreement to buy immunology and inflammation specialist Merida.

News

Isomab has presented landmark safety data at ESC, clearing the path for next-generation therapies to promote blood vessel growth in CAD.

News

AstraZeneca and Amgen have announced the first Phase III results for Tezspire (tezepelumab) in eosinophilic oesophagitis (EoE).

News

Spyre Therapeutics’ hopes for its anti-TL1A antibody SPY072 in rheumatoid arthritis (RA) have hit a bump in the road.

News

Entropy signs Pre-CTA with UCSF to develop a US-based Phase 2 trial comparing IV psilocin treatment directly against escitalopram (Lexapro) in MDD.